<DOC>
	<DOCNO>NCT00174668</DOCNO>
	<brief_summary>Primary objective : The primary study objective demonstrate superior efficacy intensify insulin regimen insulin glulisine insulin glargine two-injection conventional insulin regimen term change glycated hemoglobin A1c ( HbA1c ) , baseline endpoint . Secondary objective : Secondary study objective compare intensified insulin regimen insulin glulisine insulin glargine two-injection conventional insulin regimen term blood glucose ( BG ) value ( fast , pre-/postprandial ( ppBG ) , nocturnal , mean daily , fast plasma glucose ) , daily BG profile , BG HbA1c response rate ( predefined ) , hypoglycemic event , adverse event , change late diabetes complication , weight , body-mass-index , course total daily insulin dose adjustment , blood lipid profile , microalbuminuria , standard lab quality life/treatment satisfaction .</brief_summary>
	<brief_title>Insulin Glulisine Diabetes Mellitus , Type 2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Subjects meet follow criterion consider enrollment study : Type 2 diabetes mellitus , define American Diabetes Association least five year , treat insulin least 6 month ( history ketoacidosis ) . HbA1c 7.5 % 11.0 % , inclusive prescreening prerandomization ( week 2 ) . For least 3 month prior week 8 visit , subject must stable insulin regimen two daily s.c. injection premixed insulin : NPH plus regular insulin NPH plus rapid acting insulin ( insulin lispro insulin aspart ) mixture 70/30 75/25 . `` Stable '' mean change regimen 30 % change dose . Optionally , subject treat addition metformin accord current official product information leaflet , treatment oral blood glucose lower drug allow . Documentation full ophthalmologic exam ( incl . fundoscopy ) 6 month prior randomization . Women either childbearing potential ( surgically sterile , postmenopausal 2 year ) . Women childbearing potential must pregnant agree use reliable contraceptive measure duration study . Reliable contraceptive measure include follow : systemic contraceptive ( oral , implant , injection ) , diaphragm intravaginal spermicide , cervical cap , intrauterine device condom spermicide . Willing able perform specify home blood glucose monitoring otherwise comply study protocol requirement . Willing change twice daily insulin regimen regimen require four daily insulin injection . Provision sign date informed consent prior study procedure . `` Prescreening '' inform consent , obtain write subject , may use screening , full studyspecific inform consent must obtain write subject postscreening procedure . Exclusion criterion : Subjects present follow include study : Two severe hypoglycemic episode within past 3 month , hospitalization emergency room visit due poor diabetic control within past 3 month prior randomization . History hypoglycemia unawareness . Impaired hepatic function , show , limited , ALAT ( SGPT ) ASAT ( SGOT ) 2x upper limit normal measure visit 1 . Impaired renal function , show , limited , serum creatinine &gt; 177 mmol/l ( &gt; 2 mg/dl ) measure visit 1 ( low value due individual metformin intake require ) current renal dialysis . Body mass index ( BMI ) &gt; 38 kg/m2 . Any clinically significant abnormality screen laboratory evaluation ( unless discuss monitor approve study management ) . Active proliferative diabetic retinopathy , define application focal panretinal photocoagulation vitrectomy , 6 month prior visit 1 , unstable ( rapidly progress ) retinopathy may require surgical treatment ( include laser photocoagulation ) study . History hypersensitivity insulin insulin analogues excipients HMR 1964 formulation . Donation blood transfusion 2 month prior screen visit . Pregnant lactate woman , woman plan become pregnant study . Treatment investigational drug last month visit 1 ( screen ) . Mental condition render patient unable understand nature , scope , possible consequence study . Any clinically significant major organ system disease relevant cardiovascular , gastrointestinal , hepatic , neurologic , endocrine , hematologic major systemic disease make implementation protocol interpretation study result difficult . Treatment likelihood require treatment study period drug permit clinical study protocol . History drug alcohol abuse within last 2 year current addiction substance abuse . Night shift worker . Subject unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study . Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>